Pilot study of pentoxifylline in hepatopulmonary syndrome

Authors

  • Rajasekhar Tanikella,

    1. Liver Center, Division of Gastroenterology and Hepatology, University of Alabama at Birmingham, Birmingham, AL
    Search for more papers by this author
  • George M. Philips,

    1. Department of Medicine, University of Alabama at Birmingham, Birmingham, AL
    Search for more papers by this author
  • Dorothy K. Faulk,

    1. Liver Center, Division of Gastroenterology and Hepatology, University of Alabama at Birmingham, Birmingham, AL
    Search for more papers by this author
  • Steven M. Kawut,

    1. Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY
    2. Department of Epidemiology, Joseph L. Mailman School of Public Health, Columbia University, New York, NY
    Search for more papers by this author
  • Michael B. Fallon

    Corresponding author
    1. Liver Center, Division of Gastroenterology and Hepatology, University of Alabama at Birmingham, Birmingham, AL
    • University of Alabama at Birmingham, 290 MCLM, 1918 University Boulevard, Birmingham, AL 35294-0005
    Search for more papers by this author
    • Telephone: 205-975-5676; FAX: 205-975-9777


  • The ClinicalTrials.gov registration number is NCT00593658.

Abstract

Hepatopulmonary syndrome (HPS) results when chronic liver disease or portal hypertension causes intrapulmonary microvascular dilatation with hypoxemia. In experimental HPS, tumor necrosis factor alpha (TNF-α) overproduction contributes to vasodilatation, which is improved by pentoxifylline, a TNF-α inhibitor. The effectiveness of pentoxifylline in humans is unknown. The aim of this open-label, single-arm clinical trial was to assess the efficacy and tolerability of pentoxifylline in patients with cirrhosis and advanced HPS undergoing liver transplantation evaluation. Nine adults with cirrhosis and moderate to severe HPS were enrolled. All patients had an initial 2-week titration to a target dose of pentoxifylline of 400 mg by mouth every 8 hours, which was continued for 6 weeks. Baseline and follow-up arterial blood gases and TNF-α levels were evaluated. Adverse effects and tolerability were assessed. The 9 patients had a mean age of 55 ± 10 years, and 67% were female. The most common causes of cirrhosis were hepatitis C virus and alcohol (55%). The mean Model for End-Stage Liver Disease score was 11 (range, 6-19), and patients had advanced hypoxemia [mean partial pressure of arterial oxygen (PaO2) = 54 ± 12 mm Hg, mean alveolar-arterial oxygen gradient (A-a PaO2) = 57 ± 15 mm Hg]. Of the 9 patients enrolled, follow-up blood gases were done in 7. There was no significant change in PaO2 (P = 0.3) or A-a PaO2 (P = 0.3) with treatment. Pentoxifylline was poorly tolerated. Nausea (100%) and vomiting (56%) were the predominant side effects, and only a single patient was able to complete full-dose therapy. Treatment with pentoxifylline did not improve arterial oxygenation in advanced HPS, and tolerance was limited by gastrointestinal toxicity. Liver Transpl 14:1199–1203, 2008. © 2008 AASLD.

Ancillary